This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (20)  • Contact me when this article is cited  Related Content  • Related letter  • Related article  • Similar articles in JAMA  Topic Collections  • Pulmonary Diseases  • Asthma  • Immunology  • Allergy  • Alert me on articles by topic  Social Bookmarking   What's this?

Sally E. Wenzel, MD

JAMA. 1998;280:2068-2069.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

INTRODUCTION

DESPITE ADVANCES in the understanding and treatment of the inflammatory processes that mediate the clinical symptoms of asthma,¹ the mortality and morbidity associated with this disease have not appreciably declined.² It continues to be imperative to develop new approaches to asthma therapy. Antileukotriene drugs are a novel form of asthma pharmacotherapy and the first new treatment strategy for chronic asthma in 20 years. In experimental studies, cysteinyl leukotrienes (LTC₄, LTD₄, and LTE₄, together known formerly as slow-reacting substance of anaphylaxis or SRS-A) were found to be extremely potent bronchoconstrictors and to attract inflammatory cells, increase mucous production, and alter vascular permeability.³ LTB₄ was found to be a potent chemoattractant for neutrophils and eosinophils, but not to have a bronchoconstrictive effect.³ The cysteinyl leukotrienes were also shown to be produced by activated inflammatory cells (eosinophils, basophils, and mast cells) known to be present in . . . [Full Text of this Article]

Efficacy

Combination Therapy

Safety

Clinical Use

From the National Jewish Medical and Research Center and the University of Colorado Health Sciences Center, Denver.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Evidence Supporting Antileukotriene Agents for Asthma
Alan S. Go and Sally E. Wenzel
JAMA. 1999;281(18):1694.
EXTRACT | FULL TEXT  

RELATED ARTICLE

December 23/30, 1998
JAMA. 1998;280(24):2185-2186.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Pharmacotherapy -- first-line maintenance therapy
CMAJ 2005;173:S28-S32.
FULL TEXT  

Urinary leukotriene LTE4 levels in non-responders to antileukotriene therapy
Lee and Green
Thorax 2004;59:727-727.
FULL TEXT  

Correlation Between Cysteinyl Leukotriene Release From Leukocytes and Clinical Response to a Leukotriene Inhibitor
Terashima et al.
Chest 2002;122:1566-1570.
ABSTRACT | FULL TEXT  

Churg-Strauss syndrome in two patients receiving montelukast
Guilpain et al.
Rheumatology (Oxford) 2002;41:535-539.
ABSTRACT | FULL TEXT  

The dental patient with asthma: An update and oral health considerations
STEINBACHER and GLICK
Journal of the American Dental Association 2001;132:1229-1239.
ABSTRACT | FULL TEXT  

Evidence Supporting Antileukotriene Agents for Asthma
Go and Wenzel
JAMA 1999;281:1694-1694.
FULL TEXT